MedPath

Safety and Efficacy of Ohhmed Treatments for the Improvement of Erectile Dysfunction - A Feasibility Study

Not Applicable
Completed
Conditions
Erectile Dysfunction
Interventions
Device: Vertica RF device
Registration Number
NCT04484090
Lead Sponsor
OHH-MED Medical Ltd
Brief Summary

Erectile dysfunction, the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance, is estimated to affect up to 30 million men in the United States. The disorder is age-associated. The available treatments include oral therapy, vacuum-constriction devices; shockwave therapy, intracavernosal injections of vasoactive agents, including alprostadil (prostaglandin E1, transurethral delivery of alprostadil, Implantation of penile prostheses.

The OhhMed Company has developed the Vertica device that provides treatments for improvement of erectile function in patients with erectile dysfunction. This study assess the safety, efficacy, ease of use, and satisfaction of the Vertica device by men with mild to moderate erectile dysfunction.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
28
Inclusion Criteria
  • IIEF-EF score of 11-24 with or without the use of medication (PDE5 inhibitors).
  • Erectile dysfunction for at least 3- months
  • Steady relationship for at least 3-months.
  • patient without sensory disorders
  • patient with established organic of erectile dysfunction
Exclusion Criteria
  • investigator's impression of expected poor patient compliance or anatomic inadequacy (penile size/girth)
  • Premature ejaculation
  • Any psychiatric disorder
  • Epilepsy
  • Peyronie 's disease/ penile curvature
  • Coagulopathy
  • Any tumor in the pelvic or penile region within the last 3 years

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
VerticaVertica RF deviceTreatment with Vertica RF device for improving erectile function for men with erectile dysfunction
Primary Outcome Measures
NameTimeMethod
Change in erectile function (EF)Baseline to 1 month post intervention

The International Index for Erectile Function (IIEF) questionnaire will be administered. This is a 15 item tool; 6 ask questions addressing Erectile function over the previous 4 weeks. Scores from 0-30 can be obtained in this domain. Scores are interpreted as follows: 0-6 = Severe dysfunction, 7-12 = Moderate dysfunction, 13-18 = mild-moderate dysfunction, 19-24 = mild dysfunction, 25-30 = No dysfunction

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Rambam Medical center

🇮🇱

Haifa, Israel

© Copyright 2025. All Rights Reserved by MedPath